Mark Wildgust
Bristol-Myers Squibb
4 Papers
1 Citations
Mark Wildgust is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Dasatinib & Imatinib. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data
Giuseppe Saglio,Hagop M. Kantarjian,Neil P. Shah,Elias Jabbour,Alfonso Quintás-Cardama,Juan Luis Steegmann,Concepción Boqué,Charles Chuah,Carolina Pavlovsky,Jiri Mayer,Jon A. Ukropec,Mark Wildgust,Andreas Hochhaus +12 more
TL;DR: More pts treated with dasatinib achieved a faster, deeper cytogenetic and molecular response, which was associated with better 3-y outcomes and lower risk of transformation to AP/BP, and the clinical importance of achieving deeper levels of cytogenic response (CCyR) at 6 mo will be presented.
43
Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma
Rafael Fonseca,Thierry Facon,Mahmoud Hashim,Sandhya Nair,Jianming He,Eric A. Ammann,Annette Lam,Mark Wildgust,Shaji Kumar +8 more
TL;DR: In this paper , the authors used a partitioned survival model to compare overall survival with different treatment sequences in the first-line (1L) and second-line setting (2L) for NDMM patients.
3-year follow-up from a randomized phase 3 trial (DASISION) Early response with dasatinib or imatinib in chronic myeloid leukemia:
Andreas Hochhaus,Dong-Wook Kim,M. Brigid Bradley-Garelik,Hesham Mohamed,Mark Wildgust,Charles Chuah,Carolina Pavlovsky,Jiri Mayer,Jorge Cortes,Hagop M. Kantarjian,Giuseppe Saglio,Juan Luis Steegmann,Neil P. Shah +12 more
- 01 Jan 2014
1
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
Elias J. Jabbour,Hagop M. Kantarjian,Giuseppe Saglio,Juan Luis Steegmann,Neil P. Shah,Concepción Boqué,Charles Chuah,Carolina Pavlovsky,Jiri Mayer,Jorge E. Cortes,Michele Baccarani,Dong-Wook Kim,M. Brigid Bradley-Garelik,Hesham Mohamed,Mark Wildgust,Andreas Hochhaus +15 more
TL;DR: The achievement of an early molecular response was predictive of improved progression-free survival and overall survival, supporting new milestones for optimal response in patients with early CML-CP treated with tyrosine kinase inhibitors.